OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell
SAN DIEGO, July 1, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (Nasdaq: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that CEO and President Punit Dhillon will ring The Nasdaq Opening Bell in celebration of the Company's listing to The Nasdaq Stock Market at 9:30 am ET on July 7, 2015 at The Nasdaq MarketSite in New York City.
"On behalf of all of our dedicated employees, investors, and stakeholders, we are honored to open the Nasdaq to celebrate OncoSec's listing on this leading stock exchange," said Punit Dhillon, CEO and President of OncoSec. "As a leader in intratumoral immunotherapy, our listing on Nasdaq marks another important milestone for OncoSec over the past year. We will continue to advance our intratumoral immunotherapies in the clinic with the goal of one day benefiting cancer patients everywhere."
OncoSec invites investors and the general public to view to the live webcast. At the time of the event, the webcast will be available via the following link: https://new.livestream.com/nasdaq/live. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
[email protected]
Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
[email protected]
Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
SOURCE OncoSec Medical Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article